Åsa Riisberg
Chairman
Åsa Riisberg is formerly a Partner and Member of the Extended Executive Committee at EQT Partners AB. She held various leadership roles during her 20 year tenure at EQT, including Global Head of Healthcare Sector, Member of the Partners Committee and various other roles. Prior to joining EQT, Mrs Riisberg was an Associate at Texas Pacific Group (UK) and an Analyst at Morgan Stanley (UK).
She currently holds board memberships in Vifor Pharma AG (Member of the Board and Chair of Audit Committee), Netcompany AS (Member of the Board and Chair of Audit Committee), F-Secure Oy, Bonnier Capital, Bonnier News, Cinder Invest and Dagens Nyheter. She holds a M.Sc. in Financial Economics and Business Administration from Stockholm School of Economics.
Mathias Uhlén, Ph.D.
Director
Prof. Uhlén is a co-founder of Atlas Antibodies AB. He is a Professor of Biotechnology at the Royal Institute of Technology in Stockholm and Program Director of the Human Protein Atlas project. Prof. Uhlén is a member of the Board of Directors of Novozymes A/S, Affibody AB, ScandiBio Therapeutics AB, ScandiEdge Therapeutics AB, and The Antibodypedia AB.
Lotta Ljungqvist, Ph.D.
Director
Dr. Ljungqvist is chairperson of SwedenBIO, Department of Biotechnology at the Royal Academy of Engineering Sciences and board member of BioArctic AB, BioLamina AB, NorthX Biologics AB, Genovis AB and Arocell AB. Previously she was CEO of Testa Center at GE Healthcare Life Sciences/Cytiva, President and CEO of GE Nordics and head of R&D BioProcess GE Healthcare Life Sciences. Other positions she has held include CEO of IMEA, VP Biopharmceutical Contract Manufacturing Organization at Biovitrum and project management positions with Pharmacia Corp & Pharmacia & Upjohn. She holds a Ph.D. in Biochemistry from the Royal Institute of Technology in Stockholm.
Louise Kores
Director
Ms. Kores is Investment Professional at Patricia Industries. She is also board member at Advanced Instruments and Chair at mumbaistockholm. Previously she was Board member at Doktor24, Memira and deputy board member at Aleris. Prior to joining Patricia Industries, she was an analyst at Goldman Sachs. She holds a M.Sc. in Financial Economics and Business Administration from Stockholm School of Economics.
Gavin Wood
Director
Gavin Wood, currently the Chief Financial Officer of Adaptimmune Therapeutics Plc (NASDAQ:ADAP), a leader in TCR T-cell therapy, has over 17 years of experience from senior roles within the life sciences sector, focusing on financial operations and strategy. Prior to joining Adaptimmune, Gavin served as the Chief Financial Officer at Abcam Plc (LSE:ABC) and Executive Vice President and Chief Financial Officer at Affymetrix Inc. (NASDAQ:AFFX).
Christian Eberle
Director
Dr. Christian Eberle comes most recently from the role as CEO of evitria, part of the Atlas Antibodes group. During his career, Christian Eberle has accumulated broad experience in business strategy as well as in research, development and manufacturing within the pharmaceutical and biotechnology industry, including CDMO companies.
Zacharias Rudberg
Deputy
Zacharias Rudberg is an investment professional at Patricia Industries where he also supports Permobil. Prior to joining Patricia Industries, Zacharias worked at Bain & Company in Stockholm. He holds an M.Sc. in Industrial Engineering and Management from the Royal Institute of Technology, partly completed at the University of Illinois.